We believe that the prognostic relevance of this finding is negligible, given the fact that only AML with a low blast count (i.e., 20–29%) is associated with a more favorable prognosis; in AML with ≥30% blasts—as was the case for both the BCL-2− and BCL-2+ subgroups—the prognostic impact of the bone marrow blast percentage at baseline has not been clearly demonstrated [24]. Here, BCL2 is linked to acute myeloid leukemia.